Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by JLGeminion Mar 20, 2011 7:42am

383 Views

Post# 18312267

JLGemini Advice

Hi, I’m JLGemini. Last May, I started posting to this discussion board to protect my investment in Oncolytics. Onc opened the year at $2.75 and closed the year at $6.73. A 145% return on one stock does wonders for your portfolio return, particularly when you are over weighted in it. During 2011, there will be many press releases from Oncolytics regarding the commercial advancement of Reolysin. Releases will include completion of phase 1 of the head and neck pivotal trial, phase II trails involving lung cancers, and trials being conducted by the US NCI. Partnership announcements are also expected with the commercialization of Reolysin in sight. The return in 2011 on Oncolytics will exceed 145%.

It is interesting to read other posts to this discussion board. Most are critical of me warning retail investors of a buy side manipulation by institutional investors. My advice to retail investors is to hold and take advantage of the buy side manipulation. My advise to institutional investors is that time is running out to acquire their positions.

Supporters of the buy side manipulation do not want retail investors to be aware of the control that they have on the market price. At last Friday’s close of $5.60 for ONC on the TSX, the market cap for Oncolytics is under $400 million. There is a disconnect between the stock price and the commercial value of the proprietary rights to Reolysin. This disconnect existed for Dendreon prior to April 2009. Dendreon is a development company, like Oncolytics, and trades on the NASDAQ under DNDN.

As you review the daily trading of Dendreon during the month of April 2009, consider the following questions. Consider why there are such strong objections to my posts. Consider why the institutional holdings reported on the NASDAQ for ONCY had a net increase of over 8 million shares. Consider what a 200% return or more will do for your portfolio. With the global economy stumbling and stable growth outlook years away, consider your options. Consider over weighting your investment in Oncolytics.

Date	Closing Price	Volume
1-Apr-09	$4.14	3,199,650
2-Apr-09	4.34	2,427,867
3-Apr-09	5.99	22,497,200
6-Apr-09	6.58	19,585,750
7-Apr-09	6.58	7,346,062
8-Apr-09	6.37	5,392,639
9-Apr-09	6.30	4,234,697
13-Apr-09	7.30	12,775,310
14-Apr-09	16.99	65,120,890
15-Apr-09	17.17	19,294,060
16-Apr-09	17.03	6,894,881
17-Apr-09	17.99	17,799,470
20-Apr-09	19.52	17,724,250
21-Apr-09	19.74	11,008,510
22-Apr-09	20.12	7,358,435
23-Apr-09	20.33	6,123,418
24-Apr-09	20.08	7,393,327
27-Apr-09	21.55	18,569,850
28-Apr-09	11.81	28,070,740
29-Apr-09	22.94	48,235,790
30-Apr-09	21.20	17,468,950
Friday		?
14-Mar-11	$32.79	2,200,469